Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2021

View Archived Issues

Blueprint Medicines to acquire LNG-451 with Lengo Therapeutics acquisition

Oncostatin M targeting as approach for treating inflammatory pruritus

Metabotropic glutamate mGlu2 receptor found to be associated with alcoholism

IBI-319, a novel CD137/PD-1 bispecific antibody with limited systemic toxicity

Shanghai Longwood Biopharmaceuticals divulges PD-1/PD-L1 interaction inhibitors

Dartmouth College discloses new GR antagonists

Txinno Bioscience presents new ENPP1 inhibitors

Eli Lilly and Company identifies CSF1R inhibitors

New RIPK1 inhibitors presented by National Institute of Pharmaceutical R&D

B-cell targeting controls chronic viral infections in mice

New transgenic hACE2-expressing mouse model shows efficacy of vaccine against brain COVID-19

Discovery of novel antifungal compounds with improved metabolic stability

PNV-2 reduces metastases in animal model of triple-negative breast cancer

Scorpion Therapeutics unveils lead programs in cancer

Polyphenylene carboxymethylene shows anti-SARS-CoV-2 activity in vitro

Janssen publishes PK/PD data for the anticoagulant-reversing agent JNJ-67842125

Indomethacin-based PROTACs show pan-coronavirus activity, including SARS-CoV-2 strains

NHD2 is essential in Leishmania independently of complex I, emerging as a potential drug target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...